Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts

Pediatrics. 2024 Jul 1;154(1):e2023065425. doi: 10.1542/peds.2023-065425.

Authors

Claire Abraham^{1

2}, Jon Hatoun^{1

2

3}, Emily Trudell Correa³, Naveed Rabbani^{4

2

3}, Louis Vernacchio^{1

2

3}

Affiliations

¹ Division of General Pediatrics.
² Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
³ Pediatric Physicians' Organization at Children's, Wellesley, Massachusetts.
⁴ Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts.

PMID: 38832426
DOI: 10.1542/peds.2023-065425

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Child
Health Services Accessibility
Healthcare Disparities*
Humans
Massachusetts
Patient Acceptance of Health Care

Substances

Antibodies, Monoclonal, Humanized